Definitive Contract 75F40119C10091

Award Date 9/7/19
Potential Completion Date 6/30/24
Potential Value $1.5M
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Danbury, CT 06810, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to the National Academy of Sciences (NAS), a non-profit organization, is for evaluating the safety and efficacy of drugs for rare diseases or conditions in the United States and the European Union. The $949,037 definitive contract, awarded by the Food and Drug Administration, a civilian agency, is for a 1.5-year period ending in January 2025. The contract does not have a set-aside designation. NAS frequently partners with other non-profit organizations, federally...
The Department of Health and Human Services' Food and Drug Administration (FDA) awarded a $1,275,361.26 definitive cost-no-fee contract to Alliance Nctn Foundation, a non-profit organization and foundation, to conduct the "Integrating Clinical Trials and Real World Endpoints Data (ICAREDATA) Data Capture and Standardization Study". This contract, with a performance period ending on September 29, 2024, is part of the FDA's broader efforts to advance regulatory science and support public...
The U.S. Department of Health and Human Services (HHS) Food and Drug Administration (FDA) awarded a $350,353 definitive contract to Northwestern University, a private research university, for a project related to patient-focused drug development (PFDD) in oncology. This contract was issued under the FDA's Oncology Center of Excellence's PFDD program, which identifies research into measurement of patient experiences. Northwestern University is serving as the prime contractor, with the...
This is a $79,500 firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA), a civilian agency, to Nortis Inc., a for-profit manufacturer of biotechnology products and services. The contract is for the provision of a Parvivo System, which is an organ-on-a-chip technology. The contract has no set-aside designation and was awarded in September 2020, with a completion date of September 2021. Nortis Inc. has received prior federal grant awards from agencies such as...
This is a federal contract award from the Food and Drug Administration (FDA) to the National Opinion Research Center (NORC) at the University of Chicago, a non-profit research organization. The $1,136,094.00 contract is for "CTP DATA HARMONIZATION SERVICES" and is a firm fixed-price delivery order with a period of performance ending on July 31, 2017. The contract is not set aside for small businesses, as NORC competes as a large non-profit organization. NORC has extensive experience...
The Department of Health and Human Services (HHS) Food and Drug Administration (FDA) awarded a $224,594.36 firm fixed price definitive contract to the National Academy of Sciences, a non-profit organization, for a Geriatric Oncology Workshop in Washington, DC. The contract was awarded on May 5, 2020 and is set to be completed by May 5, 2021. The National Academy of Sciences has experience providing advisory, research, and technical support services to various federal agencies through prime and...
This is a $179,957.00 firm fixed-price delivery order contract awarded by the Food and Drug Administration (FDA) to the National Opinion Research Center (NORC) at the University of Chicago. The contract is for CTP Data Harmonization Services and does not have a set-aside designation. NORC, a non-profit research organization, has extensive experience supporting major federal programs and often serves as a prime contractor, partnering with subcontractors as needed. The contract is part of NORC's...
The Department of Health and Human Services Food and Drug Administration awarded a $1,309,126.30 definitive, cost-no-fee contract to the National Academy of Sciences, a non-profit organization, to conduct a "HORMONES STUDY" with a completion date of September 23, 2020. The contract did not have a set-aside designation. The National Academy of Sciences has a history of providing various research, analysis, advisory, and technical support services to federal agencies through prime and...
This is a firm-fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the National Disease Research Interchange (NDRI), a non-profit organization based in Philadelphia. The contract, valued at $11,376.62, is for providing human tissue samples to support biomedical research and development initiatives. NDRI has extensive experience working on similar contracts with federal agencies...
This is a $1,904,355.00 definitive cost-no-fee contract awarded by the Food and Drug Administration (FDA), a civilian government agency, to the Institute Of Quantitative Systems Pharmacology, a non-profit organization. The contract is for basic and applied research with two key objectives: (1) to test the hypothesis that variabilities in nanoparticle (NP) properties and tumor targets cause uncertainties in "FORMULA", and (2) to develop computational models to predict the...

The National Organization For Rare Disorders Inc. (Nord), a non-profit organization, was awarded a $1,464,208.71 definitive cost plus fixed fee contract by the Food and Drug Administration (FDA), a civilian agency within the U.S. Department of Health and Human Services. The contract, awarded on September 7, 2019, supports a systems-based approach to patient-focused research and product development related to rare diseases. The contract, which does not have a set-aside designation, runs through June 30, 2024. In addition to this prime contract award, Nord has received multiple federal grant subawards to provide various goods and services in support of rare disease research and drug development initiatives.

Generated 9/7/24, 12:05 PM